AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Selling Secrets Across The Globe
Motley Fool Money
Vertex Pharmaceuticals' Development Pipeline
6min Snip
00:00
Summary
Transcript
Episode notes
The CEO of Vertex, Kewal Ramani, has a proven interest in the field beyond just business acumen. The insider holdings of this company are quite low, less than 1%. If you look at forward price to earnings ratio, for example, Gilead is somewhere around 10 or 11. On devaluation, Vertex does have a higher sticker price than many other biotech pharma companies like Gilead Amgen and BioGen.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode